Plasma Interleukin-37 is Elevated in Acute Ischemic Stroke Patients and Probably Associated With 3-month Functional Prognosis 

References

• Wu S, Wu B, Liu M, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol. 2019;18(4):394–405. doi:10.1016/S1474-4422(18)30500-330878104
   PubMed Web of Science ®Google Scholar
• Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the global burden of disease study 2013. Lancet. 2016;387(10015):251–272. doi:10.1016/S0140-6736(15)00551-626510778
   PubMed Web of Science ®Google Scholar
• Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990–2010: findings from the global burden of disease study 2010. Lancet. 2014;383(9913):245–255. doi:10.1016/S0140-6736(13)61953-424449944
   PubMed Web of Science ®Google Scholar
• Virani SS, Alonso A, Benjamin EJ, et al. Statistical update heart disease and stroke statistics-2020 update a report from the American heart association. Circulation. 2020;141. doi:10.1161/CIR.0000000000000757
   Web of Science ®Google Scholar
• Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1736–1788.30496103
   PubMed Web of Science ®Google Scholar
• Esenwa CC, Elkind MS. Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. Nat Rev Neurol. 2016;12(10):594–604. doi:10.1038/nrneurol.2016.12527615422
   PubMed Web of Science ®Google Scholar
• Konsman JP, Drukarch B, Van Dam AM. (Peri)vascular production and action of pro-inflammatory cytokines in brain pathology. Clin Sci (Lond). 2007;112:1–25.17132137
   PubMed Web of Science ®Google Scholar
• Jin R, Liu L, Zhang S, et al. Role of inflammation and its mediators in acute ischemic stroke. J Cardiovasc Transl Res. 2013;6(5):834–851. doi:10.1007/s12265-013-9508-624006091
   PubMed Web of Science ®Google Scholar
• Vidale S, Consoli A, Arnaboldi M, et al. Postischemic inflammation in acute stroke. J Clin Neurol. 2017;13(1):1–9. doi:10.3988/jcn.2017.13.1.128079313
   PubMed Web of Science ®Google Scholar
• Tsuyama J, Nakamura A, Ooboshi H, et al. Pivotal role of innate myeloid cells in cerebral post-ischemic sterile inflammation. Semin Immunopathol. 2018;40(6):523–538. doi:10.1007/s00281-018-0707-830206661
   PubMed Web of Science ®Google Scholar
• Nold MF, Nold-Petry CA, Zepp JA, et al. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11(11):1014–1022. doi:10.1038/ni.194420935647
   PubMed Web of Science ®Google Scholar
• Ding VA, Zhu Z, Mantz AA, et al. The role of IL-37 in non-cancerous diseases. Pathol Oncol Res. 2017;23(3):463–470. doi:10.1007/s12253-016-0137-727787707
   PubMed Web of Science ®Google Scholar
• Boraschi D, Lucchesi D, Hainzl S, et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw. 2011;22(3):127–147. doi:10.1684/ecn.2011.028822047735
   PubMed Web of Science ®Google Scholar
• Li S, Amo-Aparicio J, Neff CP, et al. Role for nuclear IL-37 in the suppression of innate immunity. Proc Natl Acad Sci USA. 2019;16(10):4456–61.
   Web of Science ®Google Scholar
• Cavalli G, Dinarello CA. Suppression of inflammation and acquired immunity by IL-37. Immunol Rev. 2018;281(1):179–190. doi:10.1111/imr.1260529247987
   PubMed Web of Science ®Google Scholar
• Wu B, Meng K, Ji Q, et al. IL-37 ameliorates myocardial ischaemia/reperfusion injury in mice. Clin Exp Immunol. 2014;176(3):438–451. doi:10.1111/cei.1228424527881
   PubMed Web of Science ®Google Scholar
• Zhang SR, Nold MF, Tang S-C, et al. IL-37 increases in patients after ischemic stroke and protects from inflammatory brain injury, motor impairment and lung infection in mice. Sci Rep. 2019;9(1):6922. doi:10.1038/s41598-019-43364-731061403
   PubMed Web of Science ®Google Scholar
• Cavalli G, Justice JN, Boyle KE, et al. IL 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. Proc Natl Acad Sci U S A. 2017;114(9):2313–2318. doi:10.1073/pnas.161901111428193888
   PubMed Web of Science ®Google Scholar
• Zafar A, Ikram A, Jillella DV, et al. Measurement of elevated IL-37 levels in acute ischemic brain injury: a cross-sectional pilot study. Cureus. 2017;9(10):e1767. doi:10.7759/cureus.176729234571
   PubMed Web of Science ®Google Scholar
• Ji Q, Zeng Q, Huang Y, et al. Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. Mediators Inflamm. 2014;2014:165742. doi:10.1155/2014/16574224733959
   PubMed Web of Science ®Google Scholar
• Liu K, Tang Q, Zhu X, et al. IL-37 increased in patients with acute coronary syndrome and associated with a worse clinical outcome after ST-segment elevation acute myocardial infarction. Clin Chim Acta. 2017;468:140–144. doi:10.1016/j.cca.2017.02.01728237549
   PubMed Web of Science ®Google Scholar
• Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20(7):864–870. doi:10.1161/01.STR.20.7.8642749846
   PubMed Web of Science ®Google Scholar
• Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke. 1993;24(1):35–41. doi:10.1161/01.STR.24.1.357678184
   PubMed Web of Science ®Google Scholar
• Iłzecka J, Stelmasiak Z. Practical significance of ischemic stroke OCSP (Oxfordshire community stroke project) classification. Neurol Neurochir Pol. 2000;34:11–22.
   PubMedGoogle Scholar
• Sims JR, Gharai LR, Schaefer PW, et al. ABC/2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes. Neurology. 2009;72(24):2104–2110. doi:10.1212/WNL.0b013e3181aa532919528517
   PubMed Web of Science ®Google Scholar
• Bonita R, Beaglehole R. Recovery of motor function after stroke. Stroke. 1988;19(12):1497–1500. doi:10.1161/01.STR.19.12.14973201508
   PubMed Web of Science ®Google Scholar
• Katan M, Fluri F, Morgenthaler NG, et al. Copeptin: a novel, inde- pendent prognostic marker in patients with ischemic stroke. Ann Neurol. 2009;66(6):799–808. doi:10.1002/ana.2178320035506
   PubMed Web of Science ®Google Scholar
• Shou X, Lin J, Xie C, et al. Plasma IL-37 elevated in patients with chronic heart failure and predicted major adverse cardiac events: a 1-year follow-up study. Dis Markers. 2017;2017:9134079. doi:10.1155/2017/913407928781417
   PubMed Web of Science ®Google Scholar
• Wang X, Cai X, Chen L, et al. The evaluation of plasma and leukocytic IL-37 expression in early inflammation in patients with acute ST-segment elevation myocardial infarction after PCI. Mediators Inflamm. 2015;2015:626934. doi:10.1155/2015/62693425960620
   PubMed Web of Science ®Google Scholar
• Banchereau J, Pascual V, O’Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol. 2012;13(10):925–931. doi:10.1038/ni.240622990890
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–1143. doi:10.1161/hc0902.10435311877368
   PubMed Web of Science ®Google Scholar
• Endres M, Engelhardt B, Koistinaho J, et al. Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis. 2008;25(3):268–278. doi:10.1159/00011803918292653
   PubMed Web of Science ®Google Scholar
• Macrez R, Ali C, Toutirais O, et al. Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurol. 2011;10(5):471–480. doi:10.1016/S1474-4422(11)70066-721511199
   PubMed Web of Science ®Google Scholar
• Prass K, Meisel C, Hoflich C, et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med. 2003;198(5):725–736. doi:10.1084/jem.2002109812939340
   PubMed Web of Science ®Google Scholar
• Amantea D, Nappi G, Bernardi G, et al. Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J. 2009;276(1):13–26. doi:10.1111/j.1742-4658.2008.06766.x19087196
   PubMed Web of Science ®Google Scholar
• Allan SM, Tyrrell PJ, Rothwell NJ. IL-1 and neuronal injury. Nat Rev Immunol. 2005;5(8):629–640. doi:10.1038/nri166416034365
   PubMed Web of Science ®Google Scholar
• McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation. 2008;5(1):45. doi:10.1186/1742-2094-5-4518925972
   PubMed Web of Science ®Google Scholar
• Hayakawa K, Mishima K, Nozako M, et al. Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. Stroke. 2008;39(3):951–958. doi:10.1161/STROKEAHA.107.49582018258837
   PubMed Web of Science ®Google Scholar
• Felger JC, Abe T, Kaunzner UW, et al. Brain dendritic cells in ischemic stroke: time course, activation state, and origin. Brain Behav Immun. 2010;24(5):724–737. doi:10.1016/j.bbi.2009.11.00219914372
   PubMed Web of Science ®Google Scholar
• Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, et al. Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. Heart. 2004;90(8):847–852. doi:10.1136/hrt.2003.01582615253949
   PubMed Web of Science ®Google Scholar
• Wang X, Keye X, Chen S, et al. Role of IL-37 in inflammatory and autoimmune diseases. Iran J Immunol. 2018;15(3):165–174. doi:10.22034/IJI.2018.3938630246692
   PubMed Web of Science ®Google Scholar
• Fassbender K, Rossol S, Kammer T, et al. Pro-inflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci. 1994;122(2):135–139. doi:10.1016/0022-510X(94)90289-58021695
   PubMed Web of Science ®Google Scholar
• Duello KM, Nagel JP, Blackshear JL, et al. B-type natriuretic peptides and mortality after stroke: a systematic review and meta-analysis. Neurology. 2014;83(3):292–293. doi:10.1212/WNL.000000000000063425024445
   PubMed Web of Science ®Google Scholar
• Zhu Z, Xu T, Guo D, et al. Serum hepatocyte growth factor is probably associated with 3-month prognosis of acute ischemic stroke. Stroke. 2018;49(2):377–383. doi:10.1161/STROKEAHA.117.01947629321335
   PubMed Web of Science ®Google Scholar
• Hughes PM, Allegrini PR, Markus R, et al. Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. J Cereb Blood Flow Metab. 2002;22(3):308–317. doi:10.1097/00004647-200203000-0000811891436
   PubMed Web of Science ®Google Scholar